Risks

Liquidity remains extremely tight, with a 0.14 current ratio and 0.10 quick ratio, leaving MEDS more exposed than better-capitalized peers to working-capital shocks and refinancing pressure.

Interest coverage is deeply negative, indicating operating losses are still absorbing cash and making MEDS materially less resilient than profitable peers if funding conditions tighten.

A very long cash conversion cycle, driven by 255 days of payables outstanding, suggests supplier dependence and payment-stretching risk that can constrain growth versus peers with cleaner cash cycles.

Negative net debt to EBITDA reflects earnings weakness rather than balance-sheet strength, so MEDS has less flexibility than peers to absorb demand softness or margin compression.

Opportunities

If MEDS can sustain supplier financing and inventory discipline, its negative cash conversion cycle can support near-term liquidity better than peers with slower working-capital turns.

The low inventory and receivables days indicate a relatively lean operating model, which could improve cash generation faster than peers if demand stabilizes and collections hold.

Negative net debt to EBITDA gives MEDS some optionality versus levered peers, because any earnings recovery would quickly improve balance-sheet metrics and reduce financing risk.

Overall Score

MEDS is constrained by severe liquidity and coverage pressure versus peers, while a lean working-capital profile and limited net debt provide only modest upside if operations stabilize.